Claims
- 1. A method for preventing or treating an oncological disease in a human or domesticated animal, said method comprising introducing a polynucleotide coding for a superantigen into a cell, wherein said superantigen is expressed by said cell, and providing said transformed cells to said human or animal, and wherein said superantigen comprises an M-like protein.
- 2. The method according to claim 1, wherein said M-like protein is the emmL-55 protein, or a fragment or variant thereof.
- 3. The method according to claim 1, said method further comprising use of a traditional therapeutic treatment to treat said oncological disorder.
- 4. The method according to claim 3, wherein said therapy is selected from the group consisting of surgical resection of a tumor, radiotherapy, chemotherapy, and antibody-directed antitumor therapy.
- 5. The method according to claim 1, wherein said method further comprises the use of a dendritic cell cancer vaccine.
- 6. The method according to claim 1, wherein said cells are transformed in vivo in said human or animal.
- 7. The method according to claim 1, wherein said cells are transformed in vitro.
- 8. The method according to claim 1, wherein the oncological disorder to be treated is selected from the group consisting of lynphomas, leukemias, carcinomas, sarcomas, brain tumors, gliomas, glioblastomas, neuroblastomas, melanomas, hepatomas, medulloblastomas and Wilm's tumors.
- 9. The method according to claim 1, wherein said polynucleotide coding for said superantigen is introduced into said cell using a delivery vector selected from the group consisting of adenovirus, adeno-associated virus, retrovirus, pox virus, herpes virus, plasmids, double-stranded nucleic acid and single-stranded nucleic acid.
- 10. The method according to claim 1, wherein said polynucleotide coding for said superantigen is introduced into said cell using a liposome comprising said polynucleotide.
- 11. A method for preventing or treating an oncological disease in a human or domesticated animal, said method comprising introducing a polynucleotide coding for a first superantigen into a cell, and further introducing into said cell a second polynucleotide coding for at least one viral, bacterial or eukaryotic protein that is immunogenic or immunostimulatory, wherein said first superantigen and said viral, bacterial or eukaryotic protein is expressed by said cell, and providing said transformed cells to said human or animal, and wherein superantigen comprises an M-like protein.
- 12. The method according to claim 11, wherein said bacterial or eukaryotic protein is selected from the group consisting of foreign MHC antigens, cytokines, Mycobacterium-derived antigens, porcine-derived hyperacute rejection antigens, and a second superantigen.
- 13. The method according to claim 11, wherein said M-like protein is the emmL-55 protein, or a fragment or variant thereof.
- 14. The method according to claim 11, said method further comprising use of a traditional therapeutic treatment to treat said oncological disorder.
- 15. The method according to claim 14, wherein said therapy is selected from the group consisting of surgical resection of a tumor, radiotherapy, chemotherapy, and antibody-directed antitumor therapy.
- 16. The method according to claim 11, wherein said method further comprises the use of a dendritic cell cancer vaccine.
- 17. The method according to claim 11, wherein said cells are transformed in vivo in said human or animal.
- 18. The method according to claim 11, wherein said cells are transformed in vitro.
- 19. The method according to claim 11, wherein the oncological disorder to be treated is selected from the group consisting of lymphomas, leukemias, carcinomas, sarcomas, brain tumors, gliomas, glioblastomas, neuroblastomas, melanomas, hepatomas, medulloblastomas and Wilm's tumors.
- 20. The method according to claim 11, wherein said polynucleotide coding for said superantigen and/or said polynucleotide coding for said viral, bacterial or eukaryotic protein is introduced into said cell using a delivery vector selected from the group consisting of adenovirus, adeno-associated virus, retrovirus, pox virus, herpes virus, plasmids, double-stranded nucleic acid and single-stranded nucleic acid.
- 21. The method according to claim 11, wherein said polynucleotide coding for said superantigen and/or said polynucleotide coding for said viral, bacterial or eukaryotic protein is introduced into said cell using a liposome comprising said polynucleotide.
- 22. The method according to claim 12, wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, TNFα, IFNα, IFNβ, IFNγ, GM-CSF, MIP1α, MIP1γ and TGFγ.
- 23. The method according to claim 12, wherein said foreign MHC antigen is selected from the group consisting of class I, class II and class III.
- 24. A polynucleotide molecule, wherein said polynucleotide molecule comprises a nucleotide sequence encoding an M-like protein and a nucleotide sequence encoding a foreign MHC antigen.
- 25. A cell transformed with a polynucleotide molecule, wherein said polynucleotide molecule comprises a nucleotide sequence encoding an M-like protein and a nucleotide sequence encoding a foreign MHC antigen.
CROSS-REFERENCE TO A RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/394,226, filed Sep. 13, 1999, which is a continuation of International Application No. PCT/US99/00787, filed Jan. 14, 1999, which claims priority from U.S. provisional application Serial No. 60/071,497, filed Jan. 14, 1998, now abandoned.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60071497 |
Jan 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09394226 |
Sep 1999 |
US |
Child |
09950374 |
Sep 2001 |
US |
Parent |
PCT/US99/00787 |
Jan 1999 |
US |
Child |
09394226 |
Sep 1999 |
US |